DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

Key facts

Sponsor

Dizal Pharmaceuticals

Principal Investigator

Huang

Sun Yat-Sen University Cancer Center

Intervention

DZD8586+R-CHOP(drug)

Enrollment

150 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2030

Study locations (13)

• Peking University Third Hospital, Beijing, China
• Hunan Cancer Hospital, Changsha, China
• West China Hospital of Sichuan University, Chengdu, China
• Guangdong Provincial People's Hospital, Guangzhou, China
• Sun Yat-sen University Cancer Center, Guangzhou, China
• Zhujiang Hospital of Southern Medical University, Guangzhou, China
• The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
• Anhui Provincial Cancer Hospital, Hefei, China
• Linyi Cancer Hospital, Linyi, China
• Shanxi Cancer Hospital, Taiyuan, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
• The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
• Henan Cancer Hospital, Zhengzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary cutaneous diffuse large B-cell lymphoma, leg type

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07368270
  Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
  Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
• RECRUITINGPHASE2NCT06570447
  Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Primary cutaneous diffuse large B-cell lymphoma, leg type →